Sector Watch: Healthcare - Sep 07 2018
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $117.74 -0.68 -0.57% | XBI: $96.41 -0.28 -0.29% | Updated Sep 07, 2018 04:26 PM
| HEALTHCARE STOCKS - TOP GAINERS | ||||
|---|---|---|---|---|
| BLPH Bellerophon Therapeutics $56.7M |
0.98+0.15 4.2 M 3.6x |
18% | ||
| DRNA Dicerna Pharmaceuticals $784.2M |
14.81+1.79 4.4 M 10.0x |
14% | ||
| BLFS BioLife Solutions $379.1M |
21.19+2.54 636.5 K 1.8x |
14% | ||
| GALT Galectin Therapeutics $243.9M |
5.96+0.52 660.1 K |
10% | ||
| SMLR52WH Semler Scientific $179.8M |
29.49+2.29 153.9 K 5.0x |
8% | ||
| HEALTHCARE STOCKS - TOP LOSERS | ||||
|---|---|---|---|---|
| ADXS52WL Advaxis $53.7M |
1.02-0.41 9.9 M 26.6x |
-29% | ||
| OPK Opko Health Inc $2.6B |
4.58-1.01 17.7 M 3.6x |
-18% | ||
| CCXI ChemoCentryx $542.6M |
10.77-1.74 325.4 K 2.0x |
-14% | ||
| MNKD MannKind $272.3M |
1.78-0.26 12.8 M 1.9x |
-13% | ||
| AFMD Affimed $283.9M |
4.55-0.55 4.0 M |
-11% | ||
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
2018 Pipeline Insights for Hyperphosphatemia by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com | Business Wire [businesswire.com]Nasdaq Halts OPKO Health, Inc. [globenewswire.com]
Hyperparathyroidism: 2018 Pipeline Insights by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com | Business Wire [businesswire.com]
Advaxis Announces Pricing of Its Public Offering of Common Stock and Warrants | Business Wire [businesswire.com]
Advaxis Announces Pricing of Its Public Offering of Common Stock and Warrants [businesswire.com]
Dicerna Announces Pricing of Follow-On Public Offering of Common Stock | Business Wire [businesswire.com]
Advaxis, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants | Business Wire [businesswire.com]
Advaxis, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants [businesswire.com]
Dicerna Announces Proposed Follow-On Public Offering of Common Stock | Business Wire [businesswire.com]
Alacrita Appoints Peter Traber to Lead Consulting on Antifibrotic Drug Development [prnewswire.com]
Dicerna Announces Proof of Concept for DCR-PHXC in the Treatment of Primary Hyperoxaluria | Business Wire [businesswire.com]
Advaxis Licenses ADXS-HER2 to OS Therapies for Evaluation in the Treatment of Osteosarcoma | Business Wire [businesswire.com]
OPKO Initiates RAYALDEE Phase 2 Trial in Dialysis Patients [globenewswire.com]
United Therapeutics and MannKind Announce Collaboration for Pulmonary Hypertension Products [globenewswire.com]
United Therapeutics And MannKind Announce Collaboration For Pulmonary Hypertension Products [prnewswire.com]
Affimed to Present at the 2018 Wells Fargo Securities Healthcare Conference [globenewswire.com]
GRDG Sciences Concludes First Round of Research Achieving Objectives Resulting in a Valuation Exceeding $500 Million [prnewswire.com]
Dicerna to Participate in Upcoming Investor Conferences | Business Wire [businesswire.com]
MannKind Corporation to Present at Upcoming Conferences [globenewswire.com]
GT Biopharma's Chairman and Chief Executive Officer Raymond W Urbanski, M.D., Ph.D Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration [prnewswire.com]
Consolidated Research: 2018 Summary Expectations for Internap, Approach Resources, Agile Therapeutics, Town Sports International, Dicerna Pharmaceuticals, and Cott ? Fundamental Analysis, Key Performance Indications [globenewswire.com]
Bellerophon Therapeutics to Present at Rodman & Renshaw 20th Annual Global Investment Conference [globenewswire.com]
Akebia Therapeutics Appoints Cynthia Smith to Its Board of Directors | Business Wire [businesswire.com]
GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration [prnewswire.com]
OPKO Health?s BioReference Laboratories to Participate in the National Cancer Institute NCI-MATCH (Molecular Analysis for Therapy Choice) Phase II Clinical Trial [globenewswire.com]
Akebia Therapeutics Appoints Cynthia Smith to Its Board of Directors | Business & Finance | manchestertimes.com [businesswire.com]
BioLife Solutions Increases Ownership in SAVSU Technologies to 44% with $5 Million Investment [prnewswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.
